Compare Niox Group Plc with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 5.46%
- The company has been able to generate a Return on Equity (avg) of 5.46% signifying low profitability per unit of shareholders funds
2
With a growth in Operating Profit of 44.64%, the company declared Very Positive results in Jun 25
3
With ROE of 7.61%, it has a very expensive valuation with a 4.13 Price to Book Value
4
Below par performance in long term as well as near term
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.32%
0%
-10.32%
6 Months
-7.95%
0%
-7.95%
1 Year
-19.65%
0%
-19.65%
2 Years
-11.04%
0%
-11.04%
3 Years
56.62%
0%
56.62%
4 Years
68.48%
0%
68.48%
5 Years
109.81%
0%
109.81%
Niox Group Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.04%
EBIT Growth (5y)
17.99%
EBIT to Interest (avg)
-1.50
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.16
Sales to Capital Employed (avg)
0.46
Tax Ratio
56.41%
Dividend Payout Ratio
142.05%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
4.78%
ROE (avg)
5.46%
Valuation key factors
Factor
Value
P/E Ratio
54
Industry P/E
Price to Book Value
4.13
EV to EBIT
27.37
EV to EBITDA
18.86
EV to Capital Employed
4.79
EV to Sales
5.53
PEG Ratio
NA
Dividend Yield
15.79%
ROCE (Latest)
17.48%
ROE (Latest)
7.61%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Dec 2017
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
41.80
36.80
13.59%
Operating Profit (PBDIT) excl Other Income
11.90
9.00
32.22%
Interest
0.20
0.20
Exceptional Items
-0.10
0.00
Consolidate Net Profit
3.40
9.50
-64.21%
Operating Profit Margin (Excl OI)
184.20%
125.00%
5.92%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 13.59% vs 17.57% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -64.21% vs -32.62% in Dec 2023
About Niox Group Plc 
Niox Group Plc
Pharmaceuticals & Biotechnology
Circassia Group Plc, formerly Circassia Pharmaceuticals Plc, is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company is primarily focused on offering its commercialized asthma management products directly to specialist physicians in various markets. The Company’s NIOX products are used to improve asthma and offers a portfolio of asthma and chronic obstructive pulmonary disease product candidates. The Company’s commercialized chronic obstructive pulmonary disease (COPD) products are Tudorza and Duaklir in the United States. The Company’s pipeline products also include late-stage nitric oxide product LungFit PH, which is a ventilator-compatible system that utilizes an electric voltage to produce precise quantities of nitric oxide from the nitrogen and oxygen in air.
Company Coordinates 
Company Details
Northbrook House, Robert Robinson Avenue , OXFORD None : OX4 4GA
Registrar Details






